Pharmacological management of renal fibrotic disease

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2006-02-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.7.4.377PMID 16503810
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms.

  2006cited by this paper
• Efficacy and safety of benazepril for advanced chronic renal insufficiency.

  2006cited by this paper
• Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.

  2005cited by this paper
• RALES, EPHESUS and redox.

  2005cited by this paper
• Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.

  2005cited by this paper
• Strategies for national health care systems in emerging countries: the case of screening and prevention of renal disease progression in Bolivia.

  2005cited by this paper
• Insights into the mechanisms of renal fibrosis: is it possible to achieve regression?

  2005cited by this paper
• Inhibition of Gene Markers of Fibrosis with a Novel Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase in Puromycin-Induced Nephritis

  2005cited by this paper
• The Latin American Dialysis and Renal Transplantation Registry Annual Report 2002.

  2005cited by this paper
• Aliskiren, a Human Renin Inhibitor, Ameliorates Cardiac and Renal Damage in Double-Transgenic Rats

  2005cited by this paper
• Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.

  2005cited by this paper
• Glomerular activin A overexpression is linked to fibrosis in anti-Thy1 glomerulonephritis.

  2005cited by this paper
• Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.

  2005cited by this paper
• Management of hypertension in chronic kidney disease: the Italian multicentric study.

  2005cited by this paper
• Effects of statin therapy on the progression of chronic kidney disease.

  2005cited by this paper
• Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

  2005influential reference
• The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway.

  2005cited by this paper
• Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients

  2005cited by this paper
• Bone Morphogenic Protein-7 Induces Mesenchymal to Epithelial Transition in Adult Renal Fibroblasts and Facilitates Regeneration of Injured Kidney*

  2005cited by this paper
• Uncontrolled blood pressure in a treated, high-risk managed care population.

  2005cited by this paper
• Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy.

  2005cited by this paper
• Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial.

  2005cited by this paper
• Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats.

  2005cited by this paper
• Relaxin Reverses Cardiac and Renal Fibrosis in Spontaneously Hypertensive Rats

  2005cited by this paper
• Control of Hypertension in Adults With Chronic Kidney Disease in the United States

  2005cited by this paper
• Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.

  2004cited by this paper
• Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study.

  2004cited by this paper
• Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature.

  2004cited by this paper
• Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats.

  2004cited by this paper
• Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo.

  2004cited by this paper
• Eplerenone Prevents Salt-Induced Vascular Remodeling and Cardiac Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats

  2004cited by this paper
• Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis: Results of a Randomized Trial

  2004cited by this paper
• The clinical implications of aldosterone escape in congestive heart failure

  2004cited by this paper
• Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats.

  2004cited by this paper
• Intrarenal Renin-Angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis.

  2004cited by this paper
• Continuum of renoprotection with Losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results: A post hoc analysis of the RENAAL trial results

  2004cited by this paper
• Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action.

  2004cited by this paper
• Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

  2004cited by this paper
• Effect of aldosterone on renal transforming growth factor-beta.

  2004cited by this paper
• Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate

  2004cited by this paper
• A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

  2003cited by this paper
• Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.

  2003cited by this paper
• Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy

  2003cited by this paper
• Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models.

  2003cited by this paper
• Hypertension and Left Ventricular Hypertrophy : The 4 E Effects of Eplerenone , Enalapril , and Eplerenone / Enalapril in Patients With Essential

  2003cited by this paper
• Diverse Effects of Increasing Lisinopril Doses on Lipid Abnormalities in Chronic Nephropathies

  2003cited by this paper
• Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis

  2003cited by this paper
• Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats.

  2003cited by this paper
• Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.

  2003cited by this paper
• Is spironolactone safe for dialysis patients?

  2003cited by this paper
• Safety of low-dose spironolactone administration in chronic haemodialysis patients.

  2003cited by this paper
• A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.

  2003cited by this paper
• Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

  2003cited by this paper
• BMP-7 counteracts TGF-β1–induced epithelial-to-mesenchymal transition and reverses chronic renal injury

  2003cited by this paper
• RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease

  2003cited by this paper
• Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein kinase-dependent pathways.

  2003cited by this paper
• Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

  2003cited by this paper
• Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases.

  2003cited by this paper
• RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

  2003cited by this paper
• Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

  2002cited by this paper
• Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

  2002cited by this paper
• Functional Significance of Prorenin Internalization in the Rat Heart

  2002cited by this paper
• Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients

  2002cited by this paper
• Dual renin-angiotensin system blockade at optimal doses for proteinuria.

  2002cited by this paper
• The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

  2001cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Improved Hypertension Management and Control: Results From the Health Survey for England 1998

  2001cited by this paper
• Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research

  2001cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• Angiotensin II, TGF-beta and renal fibrosis.

  2001cited by this paper
• Mechanisms underlying renoprotection during renin-angiotensin system blockade.

  2001cited by this paper
• PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction.

  2001cited by this paper
• Predominance of Isolated Systolic Hypertension Among Middle-Aged and Elderly US Hypertensives: Analysis Based on National Health and Nutrition Examination Survey (NHANES) III

  2001cited by this paper
• Angiotensin II, TGF-β and renal fibrosis

  2001cited by this paper
• Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction.

  2000cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney.

  2000cited by this paper
• Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney.

  2000cited by this paper
• Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats.

  1999cited by this paper
• In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia.

  1999cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients.

  1999cited by this paper
• Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).

  1998cited by this paper
• Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis.

  1998cited by this paper
• Reversal of lesions of diabetic nephropathy after pancreas transplantation.

  1998cited by this paper
• Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

  1998cited by this paper
• Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).

  1998cited by this paper
• Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade.

  1998cited by this paper
• Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

  1997cited by this paper
• Expression of transforming growth factor-beta isoforms in human glomerular diseases.

  1996cited by this paper
• Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen.

  1996cited by this paper
• Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.

  1996cited by this paper
• Expression of transforming growth factor-β isoforms in human glomerular diseases

  1996cited by this paper
• Role of aldosterone in the remnant kidney model in the rat.

  1996cited by this paper
• Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency

  1996cited by this paper
• Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells.

  1994cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1994cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1993cited by this paper
• Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta.

  1993cited by this paper

• Effect of Astragalus membranaceus and Angelica sinensis combined with Enalapril in rats with obstructive uropathy

  2010cites this paper
• Strategies for TGF-β modulation: a review of recent patents

  2009cites this paper
• NO-independent, haem-dependent soluble guanylate cyclase stimulators.

  2009cites this paper
• NO signaling through cGMP in renal tissue fibrosis and beyond: key pathway and novel therapeutic target.

  2008cites this paper
• Losartan in Marfan Syndrome—Beyond Blood Pressure Lowering Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome. Science 312: 117–121, 2006

  2006cites this paper
• Nephrology beyond JASN

  2006cites this paper
• Nephrologie 2005/2006

  2006cites this paper
• NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

  2006cites this paper
• [Nephrology 2005/2006. Recent clinical studies and developments in science].

  2006cites this paper
• Losartan in Marfan Syndrome — Beyond Blood Pressure Lowering Losartan , an AT 1 Antagonist , Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome

  2006cites this paper